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Morphine abuse has been associated with higher virus replication and accelerated disease progression in a non-human primate model of AIDS.
In our previous report, we have shown that 50% of morphine-addicted macaques progress rapidly and that 2/3 of the rapid progressors exhibit
severe neuropathogenesis. In this report, we examined the sequence evolution of the SIV Tat protein, known to participate in AIDS
neuropathology, in the cerebrospinal fluid (CSF) of morphine-dependent and control macaques over the first 20 weeks of infection. The CSF SIV
Tat evolution was found to be inversely related with disease progression, and the highly neuropathogenic inoculum clone sequence was the
prevalent CSF form in rapid progressors. Divergence from the inoculum clone was significantly greater in both morphine-dependent normal
progressors and control macaques than in the morphine-dependent rapid progressors. Furthermore, we also found evidence of a trend that
morphine alters the type of mutation, resulting in an enhanced ratio of transitions to transversions (Ts:Tv). Rapid disease exacerbates this trend and
appears to influence the distribution of nonsynonymous changes in the first exon of SIV tat, with a clear majority of mutations occurring in the C-
terminal half of the protein where the known functionally important domains reside. Thus, morphine abuse may change the nature and extent of
mutations that drive viral evolution.
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The human immunodeficiency virus (HIV-1) is a member of
a subfamily of neurotropic viruses called the Lentivirinae
(Gonda et al., 1985). The entry of HIV-1 into the brain occurs
shortly after the host is infected and has been widely detected in
the central nervous system (CNS) by a variety of techniques
(Davis et al., 1992; Gabuzda et al., 1986; Gartner et al., 1986;
Stoler et al., 1986). The clinical consequences of HIV-1
infection of the CNS are varied and depend on both host and⁎ Corresponding author. AIDS Research Program, Ponce School of Medicine,
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Acute neuropathologies such as ataxia and meningitis are
relatively common and intermittent (Hollander and Stringari,
1987; Scarpini et al., 1991). More severe forms of HIV-1-
associated neuropathology include HIV-1 encephalitis and HIV-
1-associated dementia (HIVD), but are less frequent, occurring
in 10–20% of HIV-infected persons; and this rate may be
declining with the use of increasingly effective antiretroviral
treatment (Navia et al., 1986a, 1986b; Tozzi et al., 2005;
Maschke et al., 2000; Neuenburg et al., 2002; McCoig et al.,
2002). Typically, HIVD is a sub-cortical dementia characterized
by cognitive, behavioral and motor abnormalities (Navia et al.,
1986a, 1986b), although the clinical manifestation in the
HAART era has altered somewhat in pattern, representing
441R.J. Noel Jr. et al. / Virology 349 (2006) 440–452greater cortical involvement (Cysique et al., 2004). To date,
there have been few clear correlations between viral infection
and the development of severe neuropathology associated with
HIV-1 infection. Viral load in the plasma or CSF or particular
viral characteristics, beyond macrophage tropism, have not
proven reproducibly associated with HIVD. Rather, infiltration
of infected macrophages and the presence of multinucleated
giant cells in the brain have been strongly linked to severe
neuropathology (Anderson et al., 2002; Gonzalez et al., 2002;
Ryan et al., 2002; Gartner et al., 1986). Although the cause–
effect relationship between macrophage infiltration and HIVD
remains unclear mechanistically, a wide number of reports have
suggested specific roles for viral proteins and host factors
including genetics and lifestyle (Corder et al., 1998; Gonzalez et
al., 2002; Bell et al., 1998; Tozzi et al., 2005). Among the
clearest of behavioral correlates, HIV neuropathology has been
reported with increased frequency in the context of drug abuse
(Donahoe and Falek, 1988; Nath et al., 2002; Bell et al., 1998;
Zhang et al., 1998).
The mechanism by which drug abuse contributes to HIV
infection and pathogenesis, including neuropathogenesis, is not
completely clear, although it represents a considerable problem
for both science and society. Nearly 30% of the AIDS cases
reported in the US include injection drug abuse as a risk factor
(Purcell et al., 2004). Drug abuse itself portends a variety of
risk behaviors that assist in the spread of infection, yet there
are also cellular and biochemical changes caused by drugs of
abuse that may contribute to viral pathogenesis. Heroin, an
opiate that is converted to morphine for biological activity is a
major injected drug of abuse. Opiate drugs have controversial
effects on HIV infection and progression to AIDS, with some
studies reporting enhanced pathogenesis and others indicating
a possible survival advantage of morphine use (Chuang et al.,
2005; Kumar et al., 2004; Donahoe, 2004; Kapadia et al.,
2005). However, at the cellular level, opiates have been
reported to increase viral replication rate and rate of infection
of monocytes, upregulate chemokines and receptors and
upregulate viral gene expression (Peterson et al., 1990; Chuang
et al., 1993, 2005; Kumar et al., 2004; Li et al., 2003; Squinto
et al., 1990; Peterson et al., 1994, 2004; Steele et al., 2003).
More specifically, with respect to HIV neuropathogenesis,
opiates change the gene expression of cells in the brain causing
altered gene regulation of host cytokines, cytokine receptors as
well as the mu opioid receptor (El Hage et al., 2006; Chang et
al., 1996; Steele et al., 2003; Yu et al., 2003). Furthermore,
recent reports have indicated that opiates have synergistic
effects on glial cells in conjunction with viral proteins, such as
the viral transactivator Tat (Gurwell et al., 2001; Nath et al.,
2002; Turchan et al., 2001).
The Tat protein of primate lentiviruses has been widely
implicated as a critical viral protein in the development of
neuropathogenesis during infection (Hudson et al., 2000). Tat
can be produced and secreted from infected cells and taken up
by surrounding uninfected cells (Chang et al., 1997; Ensoli et
al., 1993; Ma and Nath, 1997). Thus, even though neurons are
not infected by HIV-1, soluble Tat can directly cause neuronal
apoptosis (Jones et al., 1998; New et al., 1997). Furthermore,Tat has been implicated as an indirect mediator of
neuropathology by its effects on other brain cells. Tat can
alter gene expression in both astrocytes and microglia,
including cytokines, chemokines, iNOS and adhesion mole-
cules (Pu et al., 2003; Woodman et al., 1999; Abraham et al.,
2003; Chauhan et al., 2003; Conant et al., 1996; Koller et al.,
2001; Kutsch et al., 2000; Liu et al., 2002; McManus et al.,
2000; Nicolini et al., 2001; Polazzi et al., 1999). In in vivo
models, the expression or application of Tat in the brain
causes changes consistent with the development of HIVD
(Jones et al., 1998; Kim et al., 2003). Finally, Tat
neuropathology may be exacerbated in the presence of
drugs of abuse. A number of recent reports have indicated
that Tat regulation of cytokine production by astrocytes, most
notably MCP-1, RANTES and IL-6, is augmented by
morphine (El Hage et al., 2005, 2006).
Regardless of the well-demonstrated combined neurotoxic-
ity of Tat and opioids in vitro, it remains unclear what may be
the relationship between morphine and Tat in the setting of
HIV-1 infection. Our morphine-dependent model of SIV/SHIV
AIDS provides an opportunity to study the possible combined
influence of Tat and morphine in vivo in the context of
disease-causing viral infection. There is convincing evidence
that morphine abuse leads to a more rapid disease in our model
(Kumar et al., 2004). Furthermore, studies in drug-abusing
populations indicated that drug abuse can contribute to
enhanced neuropathogenesis. However, it remains unclear
what are the effects of morphine and rapid disease on
neuropathogenesis in this morphine-dependent SIV/SHIV
macaque model of AIDS. This work extends our previous
study on the effect of morphine and rate of disease progression
on viral evolution of SIV Tat in the plasma and extends into
the effects on cerebrospinal fluid evolution in the same
context. As in the plasma, disease progression and extent of
evolution are inversely correlated in the CSF; however, the
pattern of changes indicates some differences that may indicate
the effects of diverse factors in the plasma and central nervous
system that drive viral evolution in the context of morphine
abuse.
Results
Analysis of the evolution of the SIV17E Tat exon 1 through 20
weeks post-infection
A total of 150 independent clones were obtained for this
study representing two time points (Table 1). Each clone was
originally amplified from viral RNA extracted from cerebro-
spinal fluid samples and covered the region from 6171 to 6661
of SIV17E-Fr. For analysis, sequences were truncated to the
amino acid coding region (nucleotides 6302 to 6597). We
focused exclusively on Tat from SIV17E-Fr based on the same
rationale as previously described (Noel and Kumar, 2006).
Particularly important among these factors was that the SIV,
rather than the two SHIV virus, showed the widest tissue
distribution as well as the earliest and most consistent invasion
into the central nervous system, within a few weeks after
Table 1
CD4+, viral load in cerebrospinal fluid and number of clones
Monkey Sampling
week a
CD4+ T
(cells/ml)
CSF viral load
(104 copies/ml)
Number of
clones b
Group A c
1/04L 12 16 37.3 9 (5)
18 2.9 226 10 (3)
1/28Q 14 21 1150 8 (2)
18 6 204 9 (6)
1/42N 12 39 17.8 9 (3)
18 10 111 8 (2)
Group B
1/02N 14 31 0.052 10 (9)
18 10 0.012 10 (3)
1/52N 14 707 below limit 5 (4)
20 1365 below limit 4 (4)
1/56L 12 31 0.023 7 (1)
20 13 0.024 5 (5)
Group C
2/02P 12 113 0.140 9 (1)
18 447 0.008 6 (3)
2/31P 12 334 0.008 8 (1)
18 214 0.008 9 (9)
2/AC42 12 154 0.140 7 (1)
18 44 0.008 17 (17)
a The sample was from cerebrospinal fluid from the indicated week post-
inoculation.
b The total number of sequenced clones is shown. The number in brackets
indicates the number of clones divergent from the inoculum.
c No Group A monkeys survived beyond week 20. 1/04L was euthanized at
week 18, 1/28Q at week 20 and 1/42N at week 19.
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in the study had detectable SIV viral RNA in the CSF.
SHIVKU1B-specific viral RNA was not found in all morphine-
dependent monkeys until week 12 and was still non-detectable
in the three control macaques at week 20. SHIV89.6P was not
detected in any of the animals in this study by week 20 post-
infection (results not shown). The total number of clones for
each animal per time point is provided in Table 1 along with
summaries of the CD4+ and cerebrospinal fluid viral loads for
the indicated time points. Of the nine animals included in this
study, six were morphine-addicted (1/04L, 1/28Q, 1/42N, 1/
02N, 1/52N, and 1/56L) forming cohort 1 and three were
morphine-free (2/02P, 2/31P, and 2/AC42) forming cohort 2.
With respect to progression, there were three groups. Among
cohort 1 animals, half progressed rapidly and maintained high
viral loads and low CD4+ counts. These animals all died on or
before the 20th week post-infection. These three animals, 1/04L,
1/28Q and 1/42N, form Group A: rapid progression + morphine
dependence. The remaining three morphine-addicted animals
showed intermediate viral loads and CD4+ counts (Group B:
normal progression + morphine dependence). Finally, the three
animals in cohort 2 that were not morphine-dependent (Group
C: normal progression, no morphine) showed the least severe
disease compared to Group A and moderately better than Group
B monkeys (Table 1). The Group A, B and C designations are
the same as used in a previous report of the plasma Tat evolution
(Noel and Kumar, 2006).Viral diversity and divergence are less in morphine-dependent
rapid progressors and viral evolution shows less complexity
Phylogenetic analyses covering the first 20 weeks of
infection showed that both diversity and divergence of the
viral quasispecies, as well as the complexity of evolution were
less in the context of rapid disease progression. Neighbor-
joining trees (Fig. 1) indicated the least overall diversity and
complexity of CSF Tat clones (open circles and triangles
represent weeks 12 and 20, respectively) in Group A animals.
All three rapid progressors were characterized almost exclu-
sively by the presence of single clone branches extending from
the root (SIV inoculum clone). On the other hand, clones from
Groups B and C monkeys showed more extensive branching
and greater complexity of evolution. This is best illustrated by
2/AC42 (Fig. 1), particularly by the 20-week time point clones;
however, all six monkeys in Groups B and C show similar
branching patterns which are absent among the rapid
progressors.
The SIV17E-Fr Tat clones from plasma from our previous
study (accession numbers: DQ007650–DQ007882; solid
circles and triangles for weeks 12 and 20, respectively)
were included in the trees to emphasize the greater
complexity of viral evolution in the normal progressors
(Noel and Kumar, 2006). Group A animals fail to form
clusters for either plasma or CSF clones; however, not only
do the normal progressors in Groups B and C demonstrate
clustering of clones, but the plasma and CSF virus also form
distinct clusters. This trend supports the notion that plasma
and CSF serve as distinct compartments of virus, as has been
shown for HIV (Tang et al., 2000; Strain et al., 2005).
Furthermore, the early appearance of SIV in the CSF (two
weeks) as compared to the late appearance of SHIVKU1B (12
weeks, in morphine-dependent macaques only) and absence
of SHIV89.6P (through 20 weeks) argues in favor of virus
compartmentalization between plasma and CSF and may
explain the generally lower viral loads in CSF (Table 1) for
each animal as compared to plasma at the same time points,
reported previously (Kumar et al., 2004; Noel and Kumar,
2006).
The viral diversity, a measure of the average distance
between all forms of a virus within an individual, and viral
divergence, a measure of the average distance between all
forms of a virus at a particular time from a unique ancestral
clone, in cerebrospinal fluid are each inversely correlated to
disease progression at the Tat locus (Fig. 2), as we reported
previously in plasma (Noel and Kumar, 2006). The three
Group A animals showed an average diversity of
0.32 ± 0.05% and divergence of 0.16 ± 0.03%. Group B
animals had average diversity and divergence values 2.8-fold
and 4.1-fold greater (0.89 ± 0.33%, P < 0.05 and
0.65 ± 0.30%, P < 0.05, respectively). Non-morphine controls
(Group C) showed greater diversity (0.59 ± 0.24%) and
divergence (0.45 ± 0.20%, P < 0.05) than Group A monkeys
by 1.8-fold and 2.8-fold, respectively. There was no statistical
difference between the diversity or divergence of Groups B
and C.
Fig. 1. Phylogenetic divergence of CSF-derived SIV Tat exon 1 clones in morphine-dependent and morphine-free SHIV/SIV-infected rhesus macaques. DNA
sequences were derived from RT-PCR of cell-free viral RNA extractions of cerebrospinal fluid (open symbols) and plasma (solid symbols) at weeks 12 (circles) and 20
(triangles) post-infection. Trees were created using BioEdit (alignment) and MEGA (tree construction and editing). Clones identical to the viral inoculum (solid
diamond, root of trees) were excluded to simplify the trees. Group A—morphine-dependent, rapid progressors. Group B—morphine-dependent, normal progressors.
Group C—non-morphine-dependent, normal progressors. Scale bars were adjusted to represent 5 changes per 1000 nucleotides for each tree.
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mutation type that is exacerbated by rapid disease progression
We categorized all unique (the same mutation in multiple
clones from a single animal was counted only once) nucleoside
substitutions as either transitions (Ts, purine to purine,
pyrimidine to pyrimidine) or transversions (Tv, purine to/from
pyrimidine) and compared the ratio (Ts:Tv) to assess the
possible roles of morphine and/or disease progression rate on
the biochemical mechanism of viral evolution. Data (Table 2)
show that the Ts:Tv ratio in monkeys treated with morphine is
2.7 to 7.5 times higher, with the greatest increase in the rapid
progressor group. Both increased transition and decreased
transversion frequencies account for this phenomenon in the
setting of morphine addiction. Transitions are nearly 15% and23% more frequent in Group A and Group B, respectively, than
in Group C. Transversions are decreased by approximately 50%
in the context of morphine treatment with normal progression.
Rapid disease progression exacerbates this phenomenon.
Transversions in Group A animals are 70% to 85% less
frequent than in Groups B and C, respectively. Interestingly,
although the total diversity and divergence among the clones in
Group A is statistically less than in normal progressors (Fig. 2),
the total number of unique mutations occurring in all groups
over the 20-week period of study was similar with 25 in Group
A, 19 in Group B and 25 in Group C (Table 2). This finding is
supported also by the shapes of the trees in Fig. 1, where rapid
progressor clones nearly all extend from the inoculum node,
while normal progressor clones show greater branching
indicative of more complex evolution.
Fig. 2. Individual and group diversity and divergence. For each macaque, all sequences were aligned using BioEdit. DNADIST (part of BioEdit package) was used to
calculate distance matrices. (A) Individual diversity was calculated by averaging all pairwise distances for all clones for each animal. Individual divergence values are
the average of all pairwise distances from each clone to the inoculum sequence. (B) Group diversity and divergence were calculated by computing the average of the
mean diversity and divergence values for each animal in each group plotted in panel A. The error bars represent the standard deviation. P values were found using a
one-tailed, unpaired t test.
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location of nonsynonymous changes, indicate support for
selective pressure; however, distinctions are evidently linked to
disease progression
The sequenced clones for each animal were examined for the
rates of synonymous and nonsynonymous substitution com-
pared to the viral inoculum sequence. This analysis was doneTable 2
Summary of all unique mutations by type and frequency per non-inoculum clone
Monkey
and group
Total unique
mutations
(Ts/Tv) a
Frequency per
unique clone b
Group average and
total c
Frequency Ts:T
Group A
1/04L 11 (10/1) Ts: 1.25, Tv: 0.13 Ts: 1.15, Tv: 0.04 24:1
1/28Q 8 (8/0) Ts: 1.00, Tv: 0.00
1/42N 6 (6/0) Ts: 1.20, Tv: 0.00
Group B
1/02N 4 (4/0) Ts: 0.80, Tv: 0.00 Ts: 1.23, Tv: 0.13 17:2
1/52N 6 (6/0) Ts: 1.50, Tv: 0.00
1/56L 9 (7/2) Ts: 1.40, Tv: 0.40
Group C
2/02P 6 (5/1) Ts: 1.25, Tv: 0.25 Ts: 1.01, Tv: 0.25 19:6
2/31P 4 (4/0) Ts: 0.80, Tv: 0.00
2/AC42 15 (10/5) Ts: 1.00, Tv: 0.50
a The same mutation in multiple identical clones is not counted multiple times w
parentheses ( ) indicate the number of transition mutations, Ts, followed by the num
b The average number of unique mutations, by type, was calculated by dividing th
c Group average transition and transversion rate per unique clone is the average of
transversions for each group were tallied. A calculated Ts:Tv ratio is provided in pa
d Synonymous and nonsynonymous mutations per respective site in each clone c
Laboratories, Sequencing Database tools). 17E vs. 12 represents changes by 12 week
e The ratio was calculated for all time points compared to the inoculum clone (17for 12-week clones, 20-week clones and all clones for each
animal (Table 2). We also compared the dS/dN ratios to probe the
potential indication of selective pressure (Lorenzo et al., 1004;
Noel and Kumar, 2006; Frost et al., 2001). The group dS/dN
ratios do not provide evidence for different selection forces
among the groups (Table 2). However, the balance between
synonymous and nonsynonymous changes at 12 and 20 weeks
post-infection shows a different trend in Group A. SynonymousFrequency of synonymous and nonsynonymous
substitutions d
Monkey
dS/dN
e
v 17E vs. 12 17E vs. 20 17E vs. all
dS dN dS dN dS dN
(24) 0.004 0 0.005 0 0.005 0 5.46
0 0 0.004 0.001 0.002 0.001 NA
0.004 0 0.003 0.001 0.003 0.001 1.79
(8.5) 0 0 0.013 0 0.007 0 5.06
0.004 0.006 0.02 0 0.011 0.003 NA
0 0.001 0.032 0 0.013 0.001 11.1
(3.2) 0 0.001 0 0.002 0 0.001 NA
0 0 0.002 0.004 0.001 0.001 3.59
0 0 0.015 0.004 0.010 0.003 4.39
ithin an individual animal—even when it appears at multiple time points. The
ber of transversion mutations, Tv.
e number of unique mutations by the number of unique clones for each animal.
the unique frequencies in the previous column. The total unique transitions and
rentheses ( ).
ompared only to the inoculum were tallied using SNAP (Los Alamos National
s, 17E vs. 20 represents changes by 20 weeks. 17E vs. all indicates all changes.
E vs. all).
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where both 1/04L and 1/42N had higher dS than dN, but in none
of the normal progressors at 12 weeks. By 20 weeks, all animals
except 2/02P favored synonymous nucleotide substitutions.
This indicates that, at 12 weeks in the normally progressing
animals, conditions permitted and/or favored nucleotide sub-
stitutions causing amino acid changes. Similarly, the distribu-
tion of nonsynonymous amino acid substitutions within the
clones in each group is distinct based on disease progression
rather than morphine abuse. Group A, B and C macaques
showed a total of 16, 9 and 21 unique amino acid substitutions
among all obtained clones (Fig. 3), however, only in rapid
progressors were changes concentrated within the C-terminal
half of Tat that contains the cysteine-rich and basic domains. In
Group A, about a third of the changes (6 of 16) were within theFig. 3. Predicted protein sequences of SIV Tat exon 1. Nucleotide sequences were ali
per time point is shown only once; in cases where multiple identical clones were fou
clone name. Sequence names (left column) indicate monkey name, week and clone n
each monkey identical to the inoculum are indicated by a solid horizontal line. Identic
(premature truncations) are indicated by an asterisk (*). The cysteine-rich and ba
respectively.first 50 amino acids, while the remainder occurred in the second
half of the first exon. The opposite pattern occurs in the
morphine-dependent normal progressors, with 2/3 of the
mutations (6 of 9) in the first 50 amino acids. Group C animals
show a roughly equal distribution of changes in the two halves
of the first exon with 12 and 9 in the first and second halves,
respectively (Fig. 3). Aside from distribution, there are no clear
substitution patterns that explain the different disease outcomes.
No animal showed substitutions in any of the seven critical
cysteines. There were noteworthy changes in charge within the
basic domain, Lys to Asp changes occurred in both 1/42N and
2/02P, but only in single clones at 18 weeks. Animals 1/04L
(Group A) and 2/AC42 (Group C) had nonsense mutations in
the basic region in one and seven clones, respectively. In the
case of 2/AC42, this change represented the major form at 18gned and translated by the standard genetic code. Each unique clone per monkey
nd, the number of independent isolates is indicated in parentheses ( ) next to the
umber. The viral inoculum is indicated by 17E in each alignment. Clones from
al positions, with respect to 17E, are indicated by a dot (.), and nonsense codons
sic domains are indicated by solid and dashed lines at the top of the figure,
446 R.J. Noel Jr. et al. / Virology 349 (2006) 440–452weeks. However, the change did not appear in other macaques.
A single clone in 2/02P at 18 weeks also showed a premature
stop mutation, but only in a single clone. More interesting in 2/
02P was the deletion of the final 28 amino acids in all 12-week
clones (Fig. 3). However, by 18 weeks, this deletion mutant was
no longer detectable, indicating a possible evolutionary dead
end.
The distribution of transition mutations reflects disease
progression
HIV-1 and SIV, among other retroviruses, possess a
propensity toward the accumulation of G to A transition
mutations. This phenomenon was reported relatively early in
the epidemic for HIV (Goodenow et al., 1989; Vartanian et al.,
1991, 1994) and shortly thereafter in SIV (Johnson et al., 1991;
Pelletier et al., 1995). Most early explanations for the observed
phenomenon were based on the high error rate of the retroviral
reverse transcriptase as well as changes in the ratios of the
intracellular nucleotide pools, particularly dTTP/dCTP (Marti-
nez et al., 1994, 1995). More recently, a host restriction
mechanism mediated by the APOBEC-3G/CEM15 protein has
been described that offers additional explanation for the
preponderance of G to A transitions known as hypermutation
(Sheehy et al., 2002). We used the HYPERMUT program (Los
Alamos National Laboratories) on our sequences to determine
the presence and pattern of transition mutations, including any
bearing G to A hypermutation signatures (Rose and Korber,
2000). Since most of our clones represented genetically intact
(without nonsense codon or frameshift) sequences capable of
encoding functional Tat protein variants, we do not assume that
the presence of hypermutation necessitates the accumulation of
defective products. This was similarly reported for smallFig. 4. Potential sites of dinucleotide and single site transition mutation. All divergen
National Laboratories) to identify sites of transitions and possible hypemutation amregions bearing limited changes for HIV-1 (Martinez et al.,
1996). Fig. 4 shows that while all three groups exhibit G to A
and non-G to A transition mutations, the patterns of transition
mutation are distinct, at least with respect to disease
progression. Most notably, as seen in the trees and inferred
amino acid sequences (Figs. 1 and 3), the Group A animals have
very few clones bearing the same transition patterns. Further-
more, only a single Group A clone, 1/04L18.10, contains
multiple potential sites. On the other hand, both groups of
normal progressors showed numerous clones with repeated sites
of transition mutations. The existence of two or three sites was
also common only to normal progressors and apparently not
affected by morphine abuse.
Discussion
This study served as a follow up to our previous work
showing that SIV Tat exon 1 sequence evolution in plasma was
inversely related to disease progression (Noel and Kumar,
2006). Regarding sequence changes, the virus in cerebrospinal
fluid showed generally the same trend as in plasma, with the
rapid progressors bearing the lowest divergence from the
inoculum clone and the lowest overall diversity among clones
for all time points. We have also found a similar pattern of
evolution of the 5′ end of SIV env as inversely related to
progression in plasma from some of these same animals (Tirado
and Kumar, 2006). However, the complexity of the evolution of
the virus in CSF, particularly with respect to disease
progression, was different. In plasma, we found that animals
in all three groups showed more frequent evolution of clones,
with nodes extending directly from the inoculum form (Noel
and Kumar, 2006). That pattern of low complexity evolution
was clearly evident in only the rapid progressors for CSFt clones were analyzed using the HYPERMUT Program Package (Los Alamos
ong all base changes.
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normally progressing Group B and C animals in this work is not
fully clear, but it may indicate the evolution of neurotropic viral
forms specific to each host as found in other viral genes during
both HIVand SIV infection (Kodama et al., 1993; Gaskill et al.,
2005; Strain et al., 2005). Still, this notion is difficult to
reconcile with the enhanced pathogenesis in the animals with
less branching as well as the known neuropathogenesis of the
parent inoculum virus SIV/17E-Fr (Overholser et al., 2003;
Zink et al., 1999, 2001).
Our findings showed some other interesting patterns that
may indicate separate contributions of opioid abuse and disease
progression rate on the mechanism of viral evolution within a
host. The data demonstrate a trend of an increasing ratio of
accumulation of transitions to transversions in the presence of
morphine. Previous groups have reported a range of Ts:Tv ratios
that can be gene-specific. While it is well described that
transitions occur with a greater frequency than transversions
(Moriyama et al., 1991), relatively few HIV studies have
endeavored to estimate the Ts:Tv ratio that best fits their data.
One study of the distribution of nonsynonymous changes that
are distant in primary structure but predicted to be proximal in
the tertiary structure of HIV Env found that a ratio of 6.1 was
optimal (Yamaguchi-Kabata and Gojobori, 2000). An exami-
nation of evolution in nine individuals with full epidemiological
information regarding transmission partners and times of
transmission indicated a Ts:Tv ratio of 3.0 to 1.42 depending
on viral gene (Leitner et al., 1997). None of these studies
reported drug abuse as a confounding factor nor was rate of
disease progression included. In our work, it appears that both
morphine and disease progression may affect the balance
between these two general classes of nucleotide substitutions,
with morphine appearing to increase the frequency of transi-
tions and rapid disease progression exhibiting a dramatic effect
on lowering the rate of transversions among Group A clones,
thus exacerbating the effect on the final ratio. We note that this
trend is based on a limited number of unique mutations (Table
2) and may also be influenced by host factors, including
genotype of the animals at loci known to affect viral mutation or
pathogenesis, such as APOBEC3G or TRIM5α in HIV
infection (Sheehy et al., 2002; Stremlau et al., 2004).
Both positive and negative selection forces have been
proposed to drive HIV evolution (Wyatt and Sodroski, 1998;
Yamaguchi-Kabata and Gojobori, 2000). Generally, evolution
favors synonymous rather than nonsynonymous changes (Li et
al., 1988); however, positive selection can drive nonsynon-
ymous changes to expand antigenic variation (Yamaguchi-
Kabata and Gojobori, 2000). In order to assess the potential for
selective forces acting on the clones in this study, we examined
rates of synonymous and nonsynonymous changes as well as
distribution of nonsynonymous changes in the known func-
tional domains of Tat. The functional domains for SIV Tat are
not as well characterized as for HIV Tat. Still, the Tat proteins of
these two lentiviruses can substitute for each other with respect
to LTR transactivation (Colombini et al., 1989), thus we
concentrated on two functional domains based on sequence
similarities between HIV and SIV Tat: the cysteine-rich region(amino acids 50–65 of SIV Tat and 22 to 37 of HIV-1 Tat) and
the basic domain (positions 80 to 90 and 49 to 57 of SIV and
HIV, respectively). The cysteine-rich region has been implicat-
ed in metal binding for dimerization as well as structural
integrity and in binding to host factors to stimulate transcription
elongation (Hoque et al., 2003; Ruben et al., 1989; Frankel et
al., 1988). This region consists of seven highly conserved
cysteine residues, alteration of which results in loss of
transactivation (Garcia et al., 1988; Ruben et al., 1989). The
second domain is a region rich in basic amino acids that is noted
for nuclear localization and in binding to the TAR loop/bulge to
mediate viral transactivation (Hauber et al., 1989; Mann and
Frankel, 1991; Rana and Jeang, 1999).
Additionally, positive selection may occur in regions
recognized by the immune system. Notably, rhesus macaques
infected with SIV have been reported to acquire CTL escape
mutations at a domain within Tat bearing the sequence
STPESANL, from amino acid 28 to 35 (Allen et al., 2000;
O'Connor et al., 2003). The most common change is serine to
proline at the first position of this motif and is detected by 14
weeks post-infection in animals of differing MHC types
(O'Connor et al., 2004). This serine to proline change emerged
by 12 weeks post-infection in the plasma virus of one of our
control animals, 2/02P (Noel and Kumar, 2006). Interestingly,
the same mutation was not discovered in 2/02P CSF clones nor
in any of the other monkey CSF clones. This further supports
the trend indicated in Fig. 1 that the virus in plasma and CSF
represent different evolutionary compartments.
Although we do not observe preferred sites of amino acid
changes among the three groups, we do find a trend of general
distribution of amino acid changes that reflects disease
progression rate rather than the presence of morphine. The
Group A monkeys show a clear majority of nonsynonymous
mutations in the C-terminal half of Tat, although without
substitution of any of the essential cysteine residues. There was
also a strong re-emergence of the inoculum virus, which is
consistent with other reports of progressive infection (Karlsson
et al., 1999), yet a substantial number of clones did arise bearing
mutations among the rapid progressors as shown in Fig. 3. It is
difficult to understand the cause and effect relationship of the
distribution of amino acid changes and rate of progression,
however, particularly in the morphine-treated animals, the
differential concentration of changes in either the N or C-
terminal half suggests a trend that was not apparent in our earlier
work with the plasma SIV Tat sequences (Noel and Kumar,
2006). Finally, the patterns of transition mutations revealed by
the HYPERMUT program (Fig. 4) lend further support to the
potential relationship between disease progression rate and the
biochemical mechanism of mutation in our model of morphine
dependence and AIDS.
It is unclear how opiates contribute to viral pathogenesis in
the CNS at the level of driving viral evolution. Our data suggest
that the effects of morphine on the infected cell may alter the
mutation rate and/or type of mutation that occurs. In terms of the
emergence of nonsynonymous changes, it is possible that rapid
disease progression is involved. We find that the distribution of
amino acid changing mutations is distinct in Group A, occurring
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important cysteine-rich and basic domains. In addition, as
others have reported, synonymous changes generally are
favored over nonsynonymous ones. This pattern emerges
quickly (by 12 weeks) only in the rapid progressors, while it
is only by 20 weeks that the normally progressing macaques,
regardless of the presence of morphine, show a dominance of
the synonymous mutation rate. It is tempting to speculate that
morphine may cause biochemical changes in the cell that
promote this effect and the impact on the Ts:Tv ratio. There
already exists evidence that morphine can contribute to an
increase in cellular reverse transcriptase activity in SIV-infected
cells (Chuang et al., 1993), which may be a sign of such a
biochemically altered intracellular environment. Furthermore, a
very recent study of the role of opioids in simian AIDS
progression indicates that the viral mutation rate in morphine-
treated animals may be subtly different (Chuang et al., 2005).
This idea merits further investigation and may help to clarify the
role that morphine plays in SIV/SHIV and, by analogy, HIV
infection.
Methods
Animal model
A total of nine male, Indian rhesus macaques (Macaca
mulatta) were used for these studies. At the start of morphine
administration, all animals ranged in age from 1.5 to 2.5
years, weighed 3 to 4.2 kg and were free of simian T-cell
leukemia virus type 1 and simian retrovirus. Animals were
treated following a protocol approved by the local animal care
committee (IACUC) in accordance with the Guide for the
Care and Use of Laboratory Animals. The morphine
addiction protocol has been described previously (Kumar et
al., 2004; Noel and Kumar, 2006; Tirado and Kumar, 2006).
Briefly, six animals (cohort 1) were made morphine-
dependent over a 20-week period prior to inoculation with
virus, while the remaining three macaques (cohort 2) were
given saline injections during the same period to serve as
controls. Cohort 1 animals were maintained at three daily
intramuscular injections of morphine (each 5 mg/kg)
throughout the study to avoid withdrawal effects. Infection
was by intravenous route with a three-virus mixture in 2 ml
containing 104 50% tissue culture infective doses each of
simian–human immunodeficiency virus KU-1B (SHIVKU-1B),
(Singh et al., 2002), SHIV89.6P (Reimann et al., 1996) and
SIV/17E-Fr (Flaherty et al., 1997). This combination of
challenge virus results in induction of uniform disease leading
to clinical AIDS in a relatively short time (Kumar et al.,
2002) rather than variably over multiple years when a single
virus is used (Kumar et al., 2001; Silverstein et al., 2000).
During the 20-week study period following inoculation, blood
and cerebrospinal fluid were collected for CBC profiles (to
obtain CD4+ cell counts, Table 1) and viral loads using a real
time RT-PCR assay with a lower limit of sensitivity of 80
copies/ml (Amara et al., 2002), as reported previously (Kumar
et al., 2004).Amplification, cloning and sequencing of 5′ exon of tat
Viral RNA was isolated from CSF samples at the
approximately 12 and 20 weeks post-infection using the
QIAmp Viral RNA Mini Kit (Qiagen, Inc., Valencia, CA). In
some cases, samples were from 14 or 18 weeks as dictated by
CSF availability (see Table 1). Primers and PCR conditions
were as reported previously. Briefly, an RT-PCR reaction was
performed using the Qiagen One-Step RT-PCR kit (primers
SvTat1F1 5′-GGCAGGGGGATGGAGACCAGG and
SvTat1R1 5′-GCACAAAAAAGGGGAATTGTCGC) fol-
lowed by a secondary PCR reaction using the Invitrogen
AccuTaq DNA polymerase (primers SvTat1F2 5′-AAATGAA-
GGACCACAAAGGGAACC and SvTat1R2 5′-CCCATAGA-
CACTTAAAAGCAAGATGGC). The 491 base pair fragment
was confirmed by agarose electrophoresis prior to cloning into
pPCR2.1 (Invitrogen, Carlsbad, CA). Positive clones were
identified by colony screening with restriction enzyme digest
(EcoR1, Promega) and agarose electrophoresis prior to liquid
culture growth and plasmid prep using the standard protocol of
the Qiagen Qiaprep Spin Mini Kit. A target of 6–10 clones per
time point were sent for sequencing to the DNA Sequencing
Facility of Florida State University, Department of Biological
Sciences. In three cases, due to low viral loads, we acquired
fewer than six clones (summarized in Table 1). Sequences of
CSF clones in this study were named as in our previous study by
monkey name then week then clone number; however, all
names were preceded by a lowercase ‘c’ to indicate CSF origin
of viral RNA. The sequences are available in GeneBank:
DQ320162–DQ320311.
Sequence editing and alignment and statistics
Sequence files (*.ab1 format) were decoded and edited using
BioEdit version 7.0.1 (Hall, 1999). Alignments were performed
via the ClustalW algorithm with the IUB DNA weight matrix
(Thompson et al., 1997) prior to truncation to the 300 bases that
encode the 99 amino acid first exon. Finally, putative amino
acid sequences were inferred from the nucleotide sequences
using the standard genetic code. All pairwise distances for
clones within each monkey (diversity) and as compared to the
inoculum clone (divergence) were calculated using DNADIST
(part of BioEdit program panel). Phylogenetic trees were
formed using a neighbor-joining method (ClustalX) (Saitou and
Nei, 1987). Group diversity and divergence were compared
statistically using an unpaired, one-tailed t test. The statistical
cut-off for significance in these analyses was P = 0.05.
Sequence analyses of mutation type, frequency and
hypermutation
Sequence changes were assessed for potential functional
changes (synonymous vs. nonsynonymous) and also based on
the character of the changes (transition vs. transversion). The
frequencies of synonymous (silent) changes per synonymous
(dS) site and nonsynonymous (amino acid changing) mutations
per nonsynonymous site (dN) for each clone compared to the
449R.J. Noel Jr. et al. / Virology 349 (2006) 440–452viral inoculum sequence were estimated using the Synonymous/
Nonsynonymous Analysis Program (SNAP) from the Los
Alamos National Laboratories (Nei and Gojobori, 1986). The
category and rate of mutation, transition or transversion, for all
point mutations were calculated from the nucleotide alignments
by comparison with the inoculum. All unique mutations were
tallied on the basis of type. If a base substitution occurred
multiple times within a single animal at the same nucleotide
position, it was counted as a single unique mutation, except in
the case where a single position had multiple different
substitutions. The frequency per unique clone was calculated
by dividing the total number of unique transition or transversion
mutations for a given animal by the total number of unique
clones. The group transition to transversion ratios (Ts:Tv) were
calculated by adding the total unique transition mutations in one
group and dividing by the sum of the unique transversion
mutations in the macaques of the same group. Potential
examples of hypermutation, the excessive accumulation of
transition mutations common to HIV and SIV, as well as other
transition mutations were computed using the HYPERMUT
program from the Los Alamos National Laboratories (Rose and
Korber, 2000).
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